InvestorsHub Logo
Post# of 4973777
Next 10
Followers 39
Posts 7322
Boards Moderated 0
Alias Born 10/17/2013

Re: None

Friday, 01/06/2023 2:35:08 AM

Friday, January 06, 2023 2:35:08 AM

Post# of 4973777
TREVENA (TRVN) : 1.83 + 8.93%
52w: 1.50 - 18.99

Total Cash (mrq) 40.39M
Total Cash Per Share (mrq) 5.81
Shares Outstanding 6.95M

https://www.trevena.com/pipeline

Trevena Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing medicines for patients affected by central nervous system (CNS) disorders. It is developing OLINVYK, a G-protein biased MOR ligand for acute pain in adults. It is developing TRV027, an angiotensin II type 1 (AT1), receptor selective agonist, for the treatment of acute lung injury contributing to acute respiratory distress syndrome (ARDS), and abnormal blood clotting in patients with COVID-19. It is developing TRV250, a G-protein biased delta-opioid receptor (DOR), is developed for the treatment of acute migraine. The Company is focused on exploring other formulations, such as transmucosal or transdermal administration for breakthrough or chronic pain, respectively. The Company is in the Phase III clinical program for OLINVO with the enrollment of patients in the ATHENA study, a Phase III, open-label, multicenter study.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.